CD8A and neoplasm: By blocking Fcγ receptors (FcγRs) before the administration of anti-programmed cell death protein 1 monoclonal antibodies (aPD-1 mAb), time for aPD-1 mAb binding to tumor-infiltrating CD8+ T cells perpetuated, which advanced tumor regression in mice treated with immunotherapy (Arlauckas and Garris, 2017).